02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Table 4.7.2 Breast cancer operation.<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

Characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Bunn<br />

2006<br />

[1]<br />

United<br />

Kingdom<br />

Systematic<br />

Review<br />

Cochrane<br />

review<br />

Metaanalysis<br />

Prophylactic ab in nonreconstructive<br />

breastcancer<br />

with placebo<br />

control. 7 studies eligible.<br />

In literature reported SSI<br />

ranges from 3%–15%. No<br />

studies with implants or<br />

reconstruction.<br />

n=1 945<br />

I: Azithromycin (dose<br />

accordingly to body weight)<br />

taken 8 pm the night before<br />

surgery. Oral clarythromycin<br />

500 mg for 10 doses,<br />

iv augmentin 1.2 g, cefazolin<br />

(6 doses) cefonicid 1 g<br />

C: Placebo Reduction in<br />

wound infection<br />

RR 0.72 (95%<br />

CI 0.53–0.97)<br />

High<br />

Authors’ conclusion:<br />

Ab should<br />

be used as one<br />

dose pre-op<br />

Tejirian<br />

2006<br />

[2]<br />

USA<br />

Metaanalysis<br />

5 studies comparing ab<br />

to placebo, 85% of the<br />

operations were performed<br />

for malignant<br />

breast disease.<br />

n=1 307<br />

I1: Cefonicid 1 g

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!